Oncology.
And the physics behind it.
Operator-led advisory across the radiation oncology landscape, proton therapy, theranostics and radiopharmaceuticals, and the broader radiation service line.
Built around radiation oncology and the modalities reshaping it.
Proton therapy, theranostics and radiopharmaceuticals, and the broader radiation oncology service line. We work with operators, investors, and health systems on the engagements where the technical, clinical, and commercial realities all collide.
Modality 01Photon Therapy
- Linear accelerator program strategy and operations
- Service line growth, referrals, and access
- Capacity planning and capital equipment decisions
Modality 02Proton Therapy
- Center development, commissioning, and ramp
- Operational turnaround for underperforming sites
- Diligence and transactions across the operator landscape
Modality 03Radiopharmaceuticals
- Theranostics program design and integration
- Isotope supply, partnerships, and logistics
- Site readiness for emerging radioligand therapies
Where the physics extends beyond the clinic.
The same accelerator and radiation expertise that powers modern oncology also underpins spaceflight, defense, and national-lab programs.
- Radiation effects testing and hardness assurance for spaceflight and defense electronics
- Government and DoD accelerator programs, from concept studies to facility delivery
- Custom accelerator projects for industrial, research, and national lab clients
- Technical diligence on accelerator and radiation-tech ventures for strategic and financial investors
Aerospace, defense & national-lab accelerator work.
Built for a niche too narrow for generalist playbooks.
Six interlocking practice areas, deliberately scoped for radiation oncology, proton therapy, and radiopharmaceuticals, not bolted on from a generalist consulting playbook.
Feasibility Analysis
Get the foundational decisions right before they become expensive to undo.
Learn moreTurnaround Services
Centers do not need a new strategy deck. They need someone who has lived inside one.
Learn moreGrowth & Referral Development
Centers do not fail because the technology underperforms. They fail because volume never shows up.
Learn moreBuy-Side Advisory
Diligence built from the inside out, for investors and operators acquiring proton centers.
Learn moreSell-Side Advisory
Position the asset on operating reality, not optimistic narrative.
Learn moreBankruptcy & Interim Leadership
Operator-grade authority for the seat that needs it now.
Learn moreWhen the technical, financial, and operational all break at once.
Operator-level experience
Decisions made by someone who has sat in the chair, not just diligenced one.
Niche depth
Radiation oncology, proton, and radiopharmaceuticals, not adjacent generalism.
Strategic judgment
Clear positions on hard calls, with the commercial reasoning to back them.
Comfort in complexity
Distressed, technical, regulated, and politically layered situations.
Every modality is bending up.
Proton centers have nearly quadrupled since 2010. Theranostics is on track to be a six-fold market. Even the mature linac base keeps growing. Pick a modality to see its trajectory.
The growth is real, but it isn't evenly distributed, and the operational reality of running these programs is what most generalist diligence misses.
Notes from the beamline.
Project milestones, market reads, and short essays on what is actually happening across radiation oncology, proton therapy, and the modalities reshaping the field.